FindTrial
Sign In

IMO-2125

DRUG5 trials

Sponsors

Amsterdam UMC, Idera Pharmaceuticals, Inc.

Conditions

Hepatitis CHepatitis C, Treatment Naïve, Genotype 1 PatientsMelanomaMetastatic MelanomaRefractory Solid TumorspT3-4 cN0M0 Melanoma

Phase 1

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
CompletedNCT00728936
Idera Pharmaceuticals, Inc.Hepatitis C
Start: 2007-09-30End: 2010-05-31Updated: 2019-02-15
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
CompletedNCT00990938
Idera Pharmaceuticals, Inc.Hepatitis C, Treatment Naïve, Genotype 1 Patients
Start: 2009-09-30End: 2011-01-31Updated: 2019-02-15
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
CompletedNCT03052205
Idera Pharmaceuticals, Inc.Melanoma, Refractory Solid Tumors
Start: 2017-06-09End: 2019-10-04Updated: 2020-02-11

Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
CompletedNCT02644967
Idera Pharmaceuticals, Inc.Metastatic Melanoma
Start: 2015-12-31End: 2021-05-31Updated: 2022-08-03
A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in clinical cT3-4N0M0 Melanoma (Intrim 1 study)
Active, not recruitingCTIS2023-509461-20-00
Amsterdam UMCpT3-4 cN0M0 Melanoma
Start: 2020-01-22Target: 214Updated: 2024-12-06

Related Papers

Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors
Cancer Research2020-08-159 citations
Abstract CT265: A phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipilimumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206)
Cancer Research2020-08-153 citations
ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.
Journal of Clinical Oncology2019-05-2012 citations
Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study
Annals of Oncology2018-10-0114 citations
ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma
Annals of Oncology2018-10-011 citations
Abstract 4704: Triple combination of IMO-2125, epacadostat and anti-PD-1 antibody demonstrates maximal antitumor efficacy and eradicates large established tumors in preclinical models
Cancer Research2018-07-012 citations
A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.
Journal of Clinical Oncology2018-05-2023 citations
Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral injection (ITI) of IMO-2125.
Journal of Clinical Oncology2018-05-202 citations
Right tumor, right time: Systematic methodology for fiducial marker placement to achieve reliable and reproducible image guided (IG) delivery of intratumoral immunotherapy into deep/visceral (D/V) lesions and target-lesion imaging follow-up.
Journal of Clinical Oncology2018-05-20
Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).
Journal of Clinical Oncology2017-03-015 citations